Hospital

December 17th 2024

The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.

December 17th 2024

Measuring end points such as molecular response, cytokines, and histomorphometry may show a greater range of benefits.

December 16th 2024

Often used as a treatment for severe exacerbations of myasthenia gravis, intravenous immunoglobulin can lead to high financial toxicity and resource utilization.

December 16th 2024

The study authors add that the validation improved the risk score in additional community-acquired pneumonia cohorts, and clinical studies would assess the broad clinical applicability.